- Home
- ENTA vs NVCT Comparison
ENTA vs NVCT Comparison
Compare ENTA & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- NVCT
- Stock Information
- Founded
- ENTA 1995
- NVCT 2020
- Country
- ENTA United States
- NVCT United States
- Employees
- ENTA N/A
- NVCT N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- ENTA Health Care
- NVCT Health Care
- Exchange
- ENTA Nasdaq
- NVCT Nasdaq
- Market Cap
- ENTA 164.6M
- NVCT 167.0M
- IPO Year
- ENTA 2013
- NVCT 2022
- Fundamental
- Price
- ENTA $8.28
- NVCT $6.16
- Analyst Decision
- ENTA Strong Buy
- NVCT Strong Buy
- Analyst Count
- ENTA 4
- NVCT 3
- Target Price
- ENTA $22.25
- NVCT $15.33
- AVG Volume (30 Days)
- ENTA 158.9K
- NVCT 65.7K
- Earning Date
- ENTA 08-11-2025
- NVCT 11-04-2025
- Dividend Yield
- ENTA N/A
- NVCT N/A
- EPS Growth
- ENTA N/A
- NVCT N/A
- EPS
- ENTA N/A
- NVCT N/A
- Revenue
- ENTA $64,806,000.00
- NVCT N/A
- Revenue This Year
- ENTA N/A
- NVCT N/A
- Revenue Next Year
- ENTA $1.65
- NVCT N/A
- P/E Ratio
- ENTA N/A
- NVCT N/A
- Revenue Growth
- ENTA N/A
- NVCT N/A
- 52 Week Low
- ENTA $4.09
- NVCT $4.44
- 52 Week High
- ENTA $13.37
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- ENTA 49.11
- NVCT 41.77
- Support Level
- ENTA $8.25
- NVCT $6.27
- Resistance Level
- ENTA $9.08
- NVCT $6.61
- Average True Range (ATR)
- ENTA 0.44
- NVCT 0.31
- MACD
- ENTA -0.08
- NVCT 0.02
- Stochastic Oscillator
- ENTA 3.78
- NVCT 1.33
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.